This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, according to research out of the University of Arizona Cancer Center in Tucson, AZ. Pyrvinium pamoate, a medication approved by the Food and Drug Administration in 1955 to treat pinworms, has been shown to have antitumor potential in several different cancers, including breast, colorectal, pancreatic, and bladder cancers.
Saying thanks can positively impact client retention. Gratitude makes the relationship more personal and builds customer loyalty. Saying thanks also encourages word-of-mouth marketing.
Jason Hawkes, MD, MS, a Dermatologist and Investigator atOregon Medical Research Center in Portland, OR,discusses the significance and implications of the U.S. Food and Drug Administrations approval of dupilumab (Dupixent, Sanofi & Regeneron) for patients aged 12+ years with uncontrolled Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite use of H1-antihistamines.It’s a win in dermatology because these are patients that we can easily recognize and diagnose and now we hav
Hair Escape, an exclusive retreat designed to provide a space for hairstylists to recharge, learn and connect, held its debut event at Gracias Madre in Jaco, Costa Rica.
We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission If youre looking to elevate your skincare routine or address specific skin concerns, face serums might be exactly what youre missing. These concentrated skincare products have taken the beauty world by storm, and as an esthetician with over 20 years of experience, Im here to break it all down for you.
We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission If youre looking to elevate your skincare routine or address specific skin concerns, face serums might be exactly what youre missing. These concentrated skincare products have taken the beauty world by storm, and as an esthetician with over 20 years of experience, Im here to break it all down for you.
James Song, MD, FAAD, discusses how the treatment of pediatric atopic dermatitis (AD) demands personalized consideration of disease severity, patient age, affected areas, and treatment history. Ruxolitinib cream may address gaps by providing a nonsteroidal alternative with fewer adverse effects, potentially delaying or reducing systemic therapy needs.
Panelists discuss how data from head-to-head clinical trials comparing different therapeutic options in atopic dermatitis inform treatment decisions while exploring critical gaps in research that future studies need to address.
James Song, MD, FAAD, discusses how ruxolitinib cream addresses a significant treatment gap in pediatric atopic dermatitis by providing a non-steroidal topical option with efficacy comparable to medium-potency corticosteroids but without the associated safety concerns.
James Song, MD, FAAD, discusses how topical Janus kinase inhibitors offer distinct advantages for children with moderate atopic dermatitis by providing effective inflammation control without the adverse effects of topical corticosteroids, particularly in sensitive areas like the face and intertriginous regions.
James Song, MD, FAAD, discusses how emerging topical JAK inhibitors like ruxolitinib cream may reduce the necessity for systemic therapies in select pediatric atopic dermatitis patients by effectively controlling moderate disease and potentially serving as long-term maintenance therapy with a favorable safety profile.
Panelists discuss how head-to-head trials in psoriasis provide direct efficacy and safety comparisons between IL-17 inhibitors and other drug classes. Studies like BE RADIANT, BE VIVID, and IXORA-R highlight bimekizumabs and ixekizumabs superiority over secukinumab and ustekinumab. CLARITY and COBRA compare IL-17 to IL-23 inhibitors, while IMMerge and BE BOLD explore risankizumabs role.
James Song, MD, FAAD, discusses how clinicians should evaluate treatment response based on objective measures including BSA involvement, EASI scores, and pruritus ratings when determining whether to escalate from topical ruxolitinib to systemic therapy or de-escalate to maintenance treatment in pediatric atopic dermatitis patients.
Panelists discuss how medical professionals anticipate new IL-17 inhibitor data, particularly from head-to-head trials like BE BOLD. Interest is growing in sonelokimab, an IL-17A/F nanobody (Papp, 2021). Further research is needed on long-term efficacy, safety, and optimal patient selection.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
75 
Let's personalize your content